UroGen Pharma Ltd. (URGN): Revenue
$109.79M
Year ended 2025-12-31
$188.73M
Trailing 12 months to 2026-06-30
+19.5%
3-year compound annual growth
+56.2%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $109.79M | +21.4% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $90.40M | +9.3% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $82.71M | +28.5% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $64.36M | +34.0% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $48.04M | +307.2% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $11.80M | n/m | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $18.0K | -98.4% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $1.13M | -86.2% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $8.16M | -53.5% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $17.53M | n/a | 2019-02-28, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $109.79M | +21.4% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $106.47M | +350.9% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $105.97M | +38.9% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $116.59M | +10.2% |
| Xencor Inc (XNCR) | 2025-12-31 | $125.58M | +13.7% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $94.57M | -31.8% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $128.87M | +0.5% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $88.04M | +376.6% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $85.33M | -6.2% |
Compare URGN, ZVRA, ZYME, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗